CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
rosiglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00381238
NCT00381238Phase 2Completed
CompareCT.gov

An Open-label Extension to Study 49653/461, to Assess the Long-term Safety of Rosiglitazone (Extended Release Tablets) in Subjects With Mild to Moderate Alzheimer's Disease

GlaxoSmithKline·interventional·Posted Sep 27, 2006·Updated May 23, 2017

In Brief

A Phase 2 clinical trial evaluating rosiglitazone for Alzheimer's Disease. Completed, enrolled 33 participants across 7 sites in 2 countries.

Detailed Summary

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 27, 2006
Enrollment StartJun 20, 2006
Primary CompletionFeb 1, 2009
Study CompletionFeb 3, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.8 years ago

Interventions

rosiglitazonedrug

Extended Release Tablets